SV| Intelligence

Since your last review

Good afternoon, Kate.

Your briefing draws on changes across scientific literature, portfolio companies, clinical development, patents, academic networks, transactions and SV’s institutional knowledge.

Your lens answers: “What has changed that I need to know?”

143new intelligence items
11material developments
4may affect an investment judgement
2deserve your attention
Priority 01Investigate

Emerging tumour biology creates a potential company-formation opportunity

Researchers associated with Oxford and the Francis Crick Institute have published converging evidence around a novel tumour-specific mechanism.

Scientific opportunity·UK·Oncology·Confidence 87%

Why this matters to SV

  • Three independent evidence streams now support the mechanism.
  • The investigator network is within two degrees of existing SV relationships.
  • No heavily financed pure-play company appears to control the emerging approach.
  • The mechanism overlaps prior SV oncology investment theses.
  • Recent pharma activity suggests increasing strategic interest in adjacent biology.
Review opportunity
Priority 02Portfolio implication

Pharma transaction changes the competitive landscape for a portfolio programme

A major pharmaceutical company has licensed an asset against an adjacent mechanism.

Portfolio intelligence·Oncology·Competitive change

Why this matters to SV

  • Provides external validation for the biological pathway.
  • Introduces a potentially better-funded competitor.
  • Changes the potential partnering landscape.
  • May affect assumptions recorded in an existing SV investment thesis.
Assess portfolio implications

How the system works

Every relevant source. The context around it. The judgement it may affect.

Sources External SV

PubMedNaturebioRxivClinicalTrials.govCRUKOxfordCambridgePatentsPortfolio updatesEmailMeeting notesInvestment memosPartner observations

Institutional intelligence

  • Change detected
  • Context retrieved
  • Prior judgement compared

Connected

Resolves to

Partner attention

A handful of developments that may deserve senior judgement.

The architecture, demonstrated

One development. Three interpretations.

Development. New independent validation emerges around Target X.

Kate

Portfolio / strategy implication

Potentially strengthens an emerging oncology thesis and warrants review against existing portfolio exposure.

Charles

Company-creation implication

Evidence threshold may now justify investigating whether the science is company-formable.

Therapeutics Team

Institutional implication

Target X has moved from Watch to Investigate based on accumulated evidence.

The evidence is shared. Relevance is personal. Institutional memory is common.

Attention asymmetries

What are we missing?

The advantage is not having more information. It is knowing what changed, why it matters, and when judgement is required.

See how institutional judgement is remembered